Ionis reports TRYNGOLZA 2025 preliminary U.S. net sales of $105M, ups peak olezarsen guidance to >$2B

IONIS PHARMACEUTICALS INC

2025-FY EPS reported -$2.38 revenue$203,330,000

TRYNGOLZA generated $105M in preliminary 2025 U.S. net product sales, outperforming expectations as first FDA-approved FCS treatment.
Annual peak net sales guidance for olezarsen in sHTG increased to >$2B from >$1B following strong Phase 3 data.
Submitted sNDA for olezarsen in severe hypertriglyceridemia; potential approval and launch anticipated in 2026.
Expects 2026 launches of zilganersen for Alexander disease (NDA in Q1) and bepirovirsen for chronic hepatitis B (with GSK).
Five Phase 3 readouts from partnered programs planned in 2026, including pelacarsen (Novartis) and eplontersen (AstraZeneca).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.